Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Obesity 3Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Metabolic Syndrome 1Kidney Neoplasms 1Inflammation 1Glioma 1Glioblastoma 1Dyslipidemias 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 25Radiotherapy 15Chemotherapy, Adjuvant 11Anastrozole 11Specimen Handling 10Neoadjuvant Therapy 8Letrozole 8Biopsy 7Radiation 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6Immunohistochemistry 5Gene Expression Profiling 5exemestane 4Surgical Procedures, Operative 4Sentinel Lymph Node Biopsy 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Psychiatric Rehabilitation 4Mass Spectrometry 4Early Intervention, Educational 4Counseling 4afimoxifene 3Trastuzumab 3Surveys and Questionnaires 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation Dose Hypofractionation 3Methods 3Mastectomy 3High-Energy Shock Waves 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡